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This guideline is a result of a consensus reached during the 19th Asian-Australasian Regional Conference of Dermatology by the 
Asian Academy of Dermatology and Venereology Study Group in collaboration with the League of Asian Dermatological Societies 
in 2010. Urticaria has a profound impact on the quality of life in Asia and the need for effective treatment is required. In line with the 
EAACI/GA
2LEN/EDF/WAO guideline for the management of urticaria the recommended ﬁrst-line treatment is new generation, non-
sedating H1-antihistamines. If standard dosing is ineffective, increasing the dosage up to four-fold is recommended. For patients who 
do not respond to a four-fold increase in dosage of non-sedating H1-antihistamines, it is recommended that therapies such as H2-
antihistamine, leukotriene antagonist, and cyclosporine A should be added to the antihistamine treatment. In the choice of second-line 
treatment, both their costs and risk/beneﬁt proﬁles are the most important considerations.
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INTRODUCTION
 
Urticaria is a heterogeneous group of diseases that result 
from a large variety of underlying and potential causes, elicited 
by a great diversity of factors [1, 2]. For a majority of patients, 
symptoms can differ by the extent of the areas affected as well 
as the severity and clinical presentation [1]. Symptoms of chronic 
urticaria can persist for 6 weeks or more and are frustrating for 
both patients and caregivers. The aim of treatment is to achieve 
complete symptom relief. Although the severity of urticaria 
may fluctuate, spontaneous remission may occur at any time [1, 
2]. However, it can take quite a long time to achieve complete 
remission. Management of chronic urticaria consists of two 
important approaches. Firstly, the identification and elimination 
of the underlying cause(s) and/or eliciting trigger(s) [1, 2]. Treating 
the cause is the most desirable option, but it is, unfortunately, 
not applicable in the majority of patients, in which urticaria 
is idiopathic [1]. Secondly, treatment is aimed at providing 
symptomatic relief [1]. In all cases, unless contraindicated, 
symptomatic relief should be offered while searching for the 
underlying cause [1]. Symptomatic treatment is currently the 
most frequent form of management. It aims to ameliorate or 
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suppress symptoms by inhibiting the release and/or the effect of 
mast cell mediators and possibly other inflammatory mediators [1, 2]. 
Health related quality of life is increasingly being recognized as 
a primary outcome in clinical trials, population studies and public 
health [1]. In treatment the patient’s well-being should be a central 
focus as chronic urticaria can persist over an extended duration 
from six weeks to over twenty years.
This guideline is a result of a consensus reached during the 19th 
Asian-Australasian Regional Conference of Dermatology by the 
Asian Academy of Dermatology and Venereology (AADV) Study 
Group in collaboration with the League of Asian Dermatological 
Societies in 2010. 
MeThODs 
The treatment options available were evaluated by the 
following methods. Information was sourced from the European 
and International guidelines for management of chronic urticaria 
and from Asian journals available from online databases such as 
MEDLINE from 2000-2010. These guidelines were then discussed 
in detail by the study group members with review of primary 
references where applicable. At a final meeting a consensus 
was obtained by means of a simple voting system. The study 
group consisted of more than 30 dermatology specialists from 13 
countries around Asia including 2 world renowned specialists in 
urticaria from Europe who are among the authors of the referenced 
European consensus [1-3]. As there is an existing international 
consensus on the definition, classification, and routine diagnosis 
of urticaria [3] which have been generally adopted in Asia, it was 
not discussed. For reference the recommended diagnostic tests in 
common urticaria types are shown in Table 1.
Management of chronic urticaria: causes and triggers 
In general the management of chronic urticaria begins with the 
identification and elimination of the underlying cause(s) and/or 
eliciting trigger(s) [1, 2]. 
During consultation the information to the patient(s) concerning 
the symptoms and advice regarding avoidance of potential triggers 
should be made available such as: alcohol overuse, excessive 
physical tiredness, mental distress, prolonged pressure on the 
skin (i.e. tight clothing & bag straps), and hot environments. The 
provision of symptomatic relief which should always be offered 
while searching for causes [1]. Avoidance of the eliciting trigger can 
be instituted for patients with IgE-mediated urticaria. A substantial 
subset of patients can have a combination of both, e.g. chronic and 
physical urticaria. These have to be identified in order for adequate 
prognosis and management. For physical urticaria the impact of 
physical stimuli can be diminished and symptoms improved by 
appropriate measures (e.g. cushioning in pressure urticaria) [1, 2]. In 
spontaneous acute and chronic urticaria, treatment of associated 
infectious and/or inflammatory processes, including Helicobacter 
pylori-associated gastritis [4], parasitic diseases [5], or food [6] and 
drug intolerance may be helpful in selected cases [1, 2]. In addition, 
it must be noted that some factors, e.g. analgesic drugs, can elicit 
new wheal formation as well as augment pre-existing urticaria [1, 
7].
Chronic urticaria is also recognized as a stress-vulnerable disease 
in which psychological stress can trigger or increase itching [1]. 
It is suggested that effective management processes could take 
into account psychological factors in some of the patients [1]. 
Many pharmacological and non-pharmacological interventions 
are available but clinical practice guidelines have created a more 
unified approach. For these reasons, the treatment regimen should 
be tailored to the individual patient. 
Identification and elimination of the underlying cause / 
potential trigger
Determining the cause of the symptoms and devising means 
of protecting the patient from further exposure will help to 
facilitate recovery. Known triggers include: drugs, food, food 
additives, infections (bacterial, viral, fungal), parasitic infestations 
and dermatological disorders [1, 6, 8]. Following elimination of the 
suspected agent, only recurrence of symptoms in a double-blind 
provocation test will provide definitive proof [1, 7]. 
Drugs  
Drugs frequently cause acute urticaria, but these can also be 
associated with chronic urticaria. When such agents are suspected 
in the course of diagnosis, they should be omitted entirely or 
substituted by another class of agents. The principle should be to 
avoid polypharmacy as far as possible, eliminating those which 
are not absolutely indispensable. Drugs causing non IgE mediated 
reactions [1] (e.g. aspirin) can not only elicit but also aggravate 
pre-existing chronic urticaria. Elimination can be expected to 
improve symptoms. Aspirin may exacerbate chronic urticaria in 
30% of patients although patients taking low dose aspirin for its 
anti-thrombotic properties can usually continue regular treatment apallergy.org
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[6]. It is advised that in the presence of chronic urticaria, aspirin 
and other nonsteroidal anti-inflammatory drugs (NSAIDs) should 
not be recommended because the potential for aggravation of 
symptoms [6, 9, 10]. Angiotensin converting enzyme inhibitors 
(ACEIs) are commonly associated with angioedema but they rarely 
cause chronic urticaria. However, ACEIs should usually be avoided 
in chronic urticaria with or without angioedema. Other drugs 
implicated include alcohol, narcotics (codeine, morphine) and oral 
contraceptives [6, 11-13].
Physical stimuli 
Avoidance of physical stimuli for the treatment of physical 
urticaria requires detailed information about the physical 
properties of the respective stimulus [1]. However, in many 
patients the threshold for the individual eliciting stimulus is low 
and thus the total avoidance of symptoms is virtually impossible 
[1, 6]. For dermographic urticaria as well as in delayed pressure 
urticaria, simple devices (such as broadening of the handle of 
heavy bags) may be helpful in the prevention of symptoms [1]. 
When considering prevention in the case of cold urticaria, the 
impact of the chill factor in cold winds needs to be taken note of [1]. 
For solar urticaria, the exact identification of the range of eliciting 
wavelengths may be important for the appropriate selection of 
sunscreens or for the selection of light bulbs with a UVA filter 
[1]; although it may be more difficult to prove in Asian countries 
subject to the availability of such facilities. 
Table 1. Recommended diagnostic tests in common urticaria subtypes 
Types Subtypes Routine diagnostic tests (recommended)
Extended diagnostic programme
* (suggested)
For identification of eliciting
factors and for ruling out possible
differential diagnoses if indicated
Spontaneous 
urticaria
Acute spontaneous urticaria
Chronic spontaneous urticaria
None
Differential blood count and ESR or CRP omission of 
suspected drugs (e.g. NSAID)
None
Test (i) infectious diseases (e.g. Helicobacter pylori); 
(ii) type I allergy;
(iii) functional autoantibodies;
(iv) thyroid hormones and autoantibodies;
(v) skin tests including physical tests;
(vi) pseudoallergen-free diet for 3 weeks and 
tryptase; 
(vii) autologous serum skin test, lesional skin biopsy
Physical urticaria Cold contact urticaria
Delayed pressure urticaria
Heat contact urticaria
Solar urticaria
Dermographic urticaria/
urticaria factitia
Cold provocation and threshold test (ice cube, cold 
water, cold wind) 
Pressure test (0.2-1.5 kg/cm
2 for 10 and 20 min)
Heat provocation and threshold test (warm water)
UV and visible light of different wave lengths
Elicit dermographism
Differential blood count and ESR/CRP
cryoproteins rule out other diseases,
especially infections
None
None
Rule out other light-induced dermatoses
Differential blood count, ESR/CRP
Other urticaria 
types 
Aquagenic urticaria
Cholinergic urticaria
Contact urticaria
Exercise-induced
anaphylaxis/urticaria
Wet cloth at body temperature
applied for 20 min
Exercise and hot bath provocation
Prick/patch test read after 20 min
According to history exercise
test with/without food but
not after a hot bath
None
None
None
None
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; NSAID, nonsteroidal anti-inflammatory drugs. 
*Depending on suspected cause. Unless strongly 
suggested by patient history, e.g. allergy. As indication of severe systemic disease. Taken from Table 5: Definition, classification, and routine diagnosis of 
urticaria: a consensus report [3]. apallergy.org
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Infections and infestations 
Among the causal factors associated with chronic urticaria, the 
following fit into this particular category. Viral infections are known 
to frequently trigger or aggravate the condition [6]. Bacterial 
infections such as dental sepsis, sinusitis, gall bladder, urinary tract 
infections and Helicobacter pylori infection have been implicated 
in chronic urticaria. Fungal infections such as onychomycosis, 
tinea pedis and candidiasis were considered as relevant 
associated treatable conditions [6]. Parasitic infestations such as 
strongyloidiasis, giardiasis and amoebiasis, are more prevalent 
particularly in developing and underdeveloped countries of Asia 
[6]. Intestinal worm infestations, almost exclusively helminthic, 
elicit eosinophilia, although the absence of eosinophilia does not 
exclude the presence of a parasite. In tropical environments it is 
easier to de-worm in all cases [5]. House dust mites are ubiquitous 
allergens and common sensitizing agents and studies from Japan 
have implicated house dust mite sensitivity in chronic urticaria 
based on intradermal skin testing and in- vitro analysis [14].
Inflammatory processes
Apart from infectious diseases, chronic inflammatory processes 
due to other diverse diseases have been identified as causative 
for urticaria in the recent past. This holds particularly for gastritis, 
reflux esophagitis, or inflammation of the bile duct or bile gland [1]. 
Functional autoantibodies 
In some patients with chronic urticaria functional autoantibodies 
against the α-chain of the high-affinity receptor for IgE (FcεRI) 
have been found to be relevant. These auto-antibodies are 
termed conditional as they only recognize unoccupied FcεRI 
[15]. The same conditional reactivity pattern has also been found 
in sera of atopic and normal healthy donors. Any condition 
resulting in accessibility of FcεRI will render these autoantibodies 
anaphylactogenic [15]. This finding offers a unifying hypothesis for 
the manifestation of different forms of urticaria. Non-immunologic 
triggers may thereby influence directly or indirectly the number of 
accessible FcεRI allowing the conditional autoantibodies to induce 
urticaria symptoms [15]. 
Systemic diseases 
Chronic urticaria can be a manifestation associated with 
hyperthyroidism and hypothyroidism (Hashimoto’s thyroiditis). 
In some euthyroid patients with autoantibodies, treatment with 
thyroxine has been reported to alleviate the urticaria [6].
Dietary management 
A practical approach would be removal or avoidance of 
suspected dietary “pseudoallergens”. However, care should be 
taken to avoid unnecessary recommendation unless backed by 
reasonable evidence. Although the patient may have reactions to 
these substances, it is noted that they may not be causative. 
In a subgroup of chronic urticaria patients, pseudoallergic 
reactions to naturally occurring food ingredients and in some 
cases to food additives are seen. If identified, the specific food 
allergens need to be omitted as far as possible but this should 
only be recommended if causality can be proven [1]. In these 
cases a diet containing only low levels of natural as well as artificial 
food pseudoallergens could be instituted and maintained for a 
prolonged period of at least 3-6 months. As they are aggravating 
factors during regular intervals of between 3-6 months these 
items can be re-introduced to the patient’s diet [1]. During this 
time spontaneous remission is achieved in approximately 50% 
of patients. It should be underlined that avoidance of type I 
allergens clears urticaria symptoms within 24-48 h if relevant 
allergens are rapidly eliminated, whereas in pseudoallergy a diet 
has often to be maintained for 2-3 weeks before beneficial effects 
can be observed [1]. IgE-mediated food allergy is rare in urticaria. 
Dietary restrictions should only be recommended if allergens 
and psuedoallergens are proven to be causative by double-blind, 
provocation tests [1, 6-8]. 
Environmental and miscellaneous triggers 
Grass pollen, mold, spores, animal dander, house dust mites 
and even tobacco smoke [16, 17] may aggravate chronic urticaria. 
Urticaria may worsen during pregnancy and also pre-menstrually. 
Urticaria has been observed in some instances to be associated 
with orthopaedic implants, dental prostheses, and with dental 
amalgams [18, 19]. Stress, depression and anxiety have been found 
to be associated as a potential causative or aggravating factor for 
urticaria [6, 20-22].
Management of chronic urticaria: treatment 
Symptomatic therapy 
These therapies aim at providing symptomatic relief to reduce 
the effect of mast cell mediators on the target organs. 
Mast cell directed therapy 
At present, the most efficient drugs inhibiting mast cell mediator apallergy.org
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release are corticosteroids. Therapies can be mast cell directed or 
at the receptor of the target organ. They should be avoided for 
long-term treatment of chronic urticaria, as dosages necessary to 
suppress symptoms are usually high with significant side-effects 
[2]. Cyclosporine also has a moderate, direct effect on mast cell 
mediator release, but this drug cannot be recommended as a 
standard treatment due to potentially severe adverse effects [2]. 
Phototherapy with ultraviolet light or photo chemotherapy (PUVA) 
reduces the numbers of mast cells in the upper dermis. It has been 
successfully used in mastocytosis and is helpful in treatment-
resistant patients with this condition [2]. 
For the treatment of chronic urticaria, UVA and UVB 
treatment for 1-3 months can be added to the antihistamine 
treatment. Although there are limited controlled studies with 
NB-UVB phototherapy, findings have found to be an effective 
complementary treatment in combination with antihistamines 
[2]. Tolerance induction may also be considered and is sometimes 
used for cold urticaria and cholinergic urticaria therapy and as a 
standard treatment for solar urticaria where even a rush therapy 
with UVA has been proven to be effective [2]. 
Therapy at the target organ
Nearly all symptoms of urticaria are mediated by H1-receptors. 
H1-receptor antagonists are thus of eminent importance in the 
treatment of urticaria. With the increased availability of this group 
of substances since the 1950s, urticaria has become one of the 
diseases that can be treated effectively with a very low adverse 
effect profile [2]. The development of second-generation non-
sedating or low-sedating antihistamines has improved the 
quality of life of urticaria patients. New generation antihistamines 
also exert anti-inflammatory effects by controlling that control 
reactions such as cytokine release from basophils and mast cells 
[2, 24]. This may be of additional benefit in controlling symptoms 
in urticaria if these effects occur at a clinically relevant dosage. The 
possibility of increased adverse cardiac effects of some second 
generation low-sedating antihistamines should be a consideration 
in the choice of the specific antihistamine, especially when 
using higher concentrations than those recommended by the 
manufacturers [2]. 
Newer antihistamines such as cetirizine, fexofenadine, and 
descarboxyloratadine, are cytochrome P450-independent 
metabolites of earlier antihistamines [2]. The main drug 
interactions with sedating antihistamines are in association 
with drugs affecting the central nervous system like analgesics, 
hypnotics, sedatives, and mood elevating drugs, as well as alcohol 
[2]. In addition, monoamine oxidase inhibitors can prolong and 
intensify anticholinergic effects. Some modern antihistamines are 
also metabolized by cytochrome P450 enzymes, and increased 
plasma levels are observed when there is concomitant treatment 
with drugs employing this enzyme system for metabolism such as 
ketoconazole or erythromycin [2]. 
Pharmacotherapy 
Depending upon the severity of the disease and response to 
various medicines, drug therapy can be considered at various levels 
as defined by four levels of therapy as discussed below (Fig. 1). 
First line therapy 
When symptoms present themselves, the first line treatment 
should be a non-sedating second generation H1-AH. Histamines 
are the main mediator of urticaria and non-sedating H1 
antihistamines represent the initial and mainstay treatment of all 
Box 1. Summary of causes and associated factors of chronic urticaria 
Possible causes and associating factors     No. (%)
Idiopathic urticaria         337 (75)
Physical urticaria           43 (9.5)
Symptomatic dermographism        17 (3.8)
Cold urticaria             8 (1.8)
Delayed pressure urticaria           7 (1.6) 
Adrenergic urticaria           6 (1.3)
Cholinergic urticaria           4 (0.9)
Solar urticaria             1 (0.2)
Infection             17 (3.8)
Dental caries             4 (0.8)
Parasitic infestation            3 (0.6)
Hepatitis             2 (0.4)
Sinusitis              2 (0.4)
Miscellaneous             6 (1.3)
Food             16 (3.6)
Thyroid diseases           15 (3.3)
Hyperthyroidism           12 (2.6)
Hypothyroidism             3 (0.6)
Dyspepsia              5 (1.1)
Atopy
*               5 (1.1)
Drugs               5 (1.1)
Collagen Vascular diseases            5 (1.1)
Others               2 (0.4)
*Urticaria wheals were frequently accompanied by an exacerbation of 
asthma, allergic rhinitis or atopic dermatitis. Taken from Table 2: Chronic 
idiopathic urticaria: prevalence and clinical course [23].apallergy.org
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Fig. 1. Recommended treatment algorithm for chronic urticaria. (Taken 
from Fig. 1: EAACI/GA²LEN/EDF/WAO guideline: management of urticaria 
[1]).
urticarias. These agents are reasonably effective for many patients 
[1, 6]. The newer generation less sedating H1 antihistamines and 
less cholinergic effects are preferred over the older generation 
H1 antihistamines as the initial choice of therapy and different 
studies on role of antihistamines in chronic urticaria showed 44 to 
91% response rate [6]. Antihistamines should be taken on regular 
basis, not as and when required to get consistent results [6]. 
Antihistamines should be given with due regard to age, pregnancy, 
state of health, and individual response. In summary, considering 
their good safety profile, second-generation antihistamines must 
be considered as first line symptomatic treatment for urticaria [6]. 
Second line therapy 
If symptoms persist after 2 weeks, the treatment regimen should 
be adjusted and non-sedating second generation H1-AH can be 
up dosed up to 4 times [1]. Even though there is available evidence 
for increased dosing [25, 26] it should be noted that up dosing is 
not a part of current labelling for non-sedating second generation 
H1-AH in Asia.
The general consensus of the group is that Asians, being 
generally of smaller physical build, dosing of antihistamines can 
be continued in smaller increments and this was believed to be 
a successful approach. Other treatment options or combination 
therapy should be attempted for best response. 
Table 2. Recommendations and suggestions for the management of 
urticaria 
We recommend the use of the treatment algorithm as described in Fig. 1
 for the symptomatic treatment of chronic spontaneous urticaria (strong,
  low quality evidence). 
In patients with urticaria and no special indication, we recommend against 
 the routine use of old sedating first generation antihistamines (strong 
 recommendation, high quality evidence). 
We recommend against the use of astemizole and terfenadine (strong 
 recommendation, high-quality evidence). 
We suggest the same first line treatment and up-dosing as described in 
 Fig. 1 for children (weight adjusted) (weak recommendation, low-quality 
 evidence). 
We suggest the same first line treatment as described in Fig. 1 in pregnant 
 or lactating women with chronic spontaneous urticaria but safety data in 
 a large meta-analysis is limited to loratadine (weak recommendation, very 
 low-quality evidence). 
Remarks: higher doses may be required, but their safety profile needs to be 
 carefully weighted against the potential additional benefit. 
Taken from Table 2: EAACI/GA²LEN/EDF/WAO guideline: management of 
urticaria [1]. 
Comments on procedure on algorithm for chronic urticaria
First level: High quality evidence 
•	 Low cost (worldwide availability also in developing countries 
mostly cheaper than older Antihistamines) 
•	 Very good safety profile 
•	 Very good evidence for efficacy 
Second level: Low quality evidence 
•	 Low cost 
•	 Good safety profile 
•	 Good evidence for efficacy 
Third level: Very low quality evidence 
•	 Low to medium-low cost 
•	 Good safety profile 
•	 Insufficient or no evidence for efficacy in high quality RCT 
Fourth level: 
•	 Cyclosporine: 
o  Medium to high cost 
o  Moderate safety profile 
o  Moderate level of evidence for efficacy 
•	 H2-Antihistamine: 
o  Low cost 
o  Good safety profile 
o  Very low level of evidence for efficacy 
•	 Dapsone: 
o  Low cost 
o  Medium level of side effects 
o  Low level of evidence for efficacy 
•	 Anti-IgE: 
o  High cost 
o  Good safety profile 
o  Low level evidence for good efficacy 
Strength of recommendation 
Recommendations are classified as “strong” or “weak” as recommended in the 
GRADE methodology. “Strong” recommendations can be interpreted as:
• Most individuals should receive the intervention
• Most well informed individuals would want the recommended course of action 
and only a small proportion would not
• Could be used for policy making or as or quality indicator.
“Weak” recommendations can be interpreted as:
• The majority of well informed individuals would want the suggested course of 
action, but an appreciable proportion would not
• Widely varying values and preferences
• Policy making or quality indicator development will require extensive debates and 
involvement of many stakeholders.apallergy.org
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Third line therapy 
If symptoms persist after a further 1-4 weeks, the treatment 
regimen of the nsAH dosage can be changed to a 1st generation 
sedating antihistamine or an alternative 2nd generation non-
sedating antihistamine with the option of adding a leukotriene 
antagonist. Should exacerbation of symptoms occur, in addition 
the patient can be put on systemic corticosteroid for 3-7 days [1]. 
The use of systemic corticosteroids in the treatment of urticaria is a 
controversial issue. Short courses of systemic steroids can be given 
in resistant cases of chronic urticaria that have not responded 
to H1 antihistamine [1, 6]. The efficacy of corticosteroid therapy 
is high, but long term therapy cannot be proposed because of 
known adverse effects, such as diabetes mellitus, hypertension, 
osteoporosis and gastrointestinal bleeding. Prolonged treatment 
of chronic urticaria with oral corticosteroids should usually 
be avoided except in disabling delayed or pressure urticaria 
and urticarial vasculitis, which are usually nonresponsive to 
antihistamines [1, 6]. Leukotriene receptor antagonists, zafirlukast 
(20 mg twice daily) and montelukast (10 mg once daily) have 
been shown to have beneficial effect in treatment of chronic 
urticaria especially in cases which were aggravated by the NSAIDs 
and food additives. Zileuton, a 5-lipooxygenase inhibitor, which 
inhibits leukotriene generation has been found to be effective in 
improving chronic urticaria [6]. 
Fourth line therapy 
If symptoms persist after a further 1-4 weeks, the treatment 
regimen of the nsAH dosage can be continued as a combination 
with the addition of a cyclosporine, second generation non-
sedating H2-antihistamine, dapsone, or omalizumab. Should 
exacerbation of symptoms occur, in addition the patient should 
be put on systemic corticosteroid for another 3-7 days [1]. Therapy 
with immunomodulating properties could be tried in patients with 
severe refractory autoimmune urticaria. Cyclosporine has been 
shown to be effective in severe unremitting urticaria that had a 
poor response to conventional treatment with antihistamines [1, 6]. 
However, it cannot be recommended as standard therapy due to 
the high incidence of adverse events [1]. 
High dose of intravenous immunoglobulin (IVIG) has been 
found to be associated with some apparent benefits in the 
treatment of chronic urticaria. Plasmapheresis has been used to 
treat some patients with autoantibody positive severe chronic 
urticaria [6]. According to some case reports oral tacrolimus, 
low dose methotrexate, hydroxychloroquine, sulfasalazine, and 
dapsone, which also have immunomodulatory properties, have 
demonstrated some efficacy in the treatment of chronic urticaria. 
However in the case of oral tacrolimus, plasmapheresis and IVIG 
access may be an issue due to availability and costs and thus not 
readily as available throughout Asia. Warfarin therapy may be 
considered in a subgroup of patients with autologous serum skin 
test negative chronic urticaria and angioedema unresponsive to 
antihistamine [6, 27]. 
Prolonged corticosteroid treatment should generally not 
be given for chronic urticaria [1, 8]; it can, however, be used in 
urticarial vasculitis and then often in combination with colchicine 
or dapsone. Cyclosporine up to 5 mg per kg per day has been 
proven effective in patients with severe chronic urticaria. 
The consensus recommendation for steroid therapy in Asian 
adults is in line with recommendations from the EAACI/GA
2LEN/
EDF/WAO guideline for the management of urticaria [1] and 
outlined in Table 2.
Further therapeutic possibilities 
Whereas antihistamines at higher concentrations will control 
symptoms in probably more than 95% of patients with urticaria, 
alternative treatments are needed for the remaining unresponsive 
patients (Table 3) [2]. Many of the alternatives are based on 
open trials or case reports. More recent approaches include 
leukotriene antagonists, interferon, or immunoglobulins [28]. On 
the other hand some treatment alternatives formerly proposed 
have been shown to be ineffective in double-blind, placebo-
controlled studies and should no longer be used [2]. These 
include tranexamic acid and sodium cromoglycate in chronic 
urticaria, nifedipine in dermographicurticaria, and colchicine and 
indomethacin in delayed pressure urticaria [2, 29].
More selective immunotherapies are possibilities. The 
extracellular part of the subunit of FcεRIa or shorter peptide 
sequences containing the autoantibody epitopes could be used to 
bind to circulating FcεRIa auto antibodies, thereby inhibiting their 
attachment to receptors on mast cells or basophils [30].
First-generation H1-antihistamines: history & caveats 
First-generation H1-antihistamines have been in clinical use 
since the 1940s and 1950s this class of drugs are still widely 
available and is the most frequent form of over-the-counter self-
medication widely used for the treatment of allergic rhinitis, 
allergic conjunctivitis, urticaria, coughs, colds and insomnia. 
Based on the European paper published by the GA
2LEN apallergy.org
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task force [31], their findings reveal that these drugs pose a 
considerable level of risk to the self-medicating general public and 
to special patient groups that are purchased over-the-counter in 
the absence of appropriate medical supervision. 
The primary reason for their choice and usage by adults has 
been their availability for decades, patient’s familiarity with them 
and their self-intuitive considerations that, “they must be both 
effective and safe”. “In fact, patients believe them to be so safe that 
the warnings on the label that the drugs may cause drowsiness 
often go unheeded, or even unread even though they have 
potentially dangerous unwanted effects [31].” 
Documented adverse effects associated with the sedating 
nature of first-generation H1-antihistamines include the following: 
• Effects to rapid eye movement sleep [31], 
• Impaired learning-cognitive impairment [31], 
•   Reduction in work efficiency - Within a small percentage 
they have been implicated in civil aviation, motor vehicle and 
boating accidents [31], and
•   Suicide in teenagers and adults [31] 
Special patient groups who are particularly at risk with first-
generation H1-antihistamines are: 
•   Infants and young children [31]
•   The elderly [31] 
•   Pregnant women [31] 
Table 3. Treatments in urticaria 
Patient 
population 
Intervention  Strength of 
recommendation
 for use of 
 intervention 
Alternative interventions (for patients who do 
not respond to other interventions) 
Quality of 
evidence 
Strength of 
recommend-
ation for use of 
intervention 
a. Acute 
spontaneous 
urticaria 
Non-sedating second 
generation H1-
antihistamine 
Strong  Prednisolone, 
2 × 20 mg/day for 4 days 
Prednisolone, 50 mg/day for 3 days 
H2-blocker, single dose for 5 days 
Low 
Very low
Very low 
Weak 
b. Chronic 
spontaneous 
urticaria 
Non-sedating (ns) 
second generation (sg) 
H1-antihistamine (AH) 
- Increase dosage if 
necessary up to four-
fold 
Strong 
Weak 
ns sg H1-AH and cyclosporine 
ns sg H1 and H2-AH 
Cimetidine 
Monotherapy 
Tricyclic antidepressants (doxepin) 
Ketotifen 
Hydroxychloroquine 
Dapsone 
Sulfasalazine 
Methotrexate 
Corticosteroids 
Other treatment options 
Combination therapy 
ns sg H1-AH and stanazolol 
ns sg H1-AH and zafirlukast 
ns sg H1-AH and Mycophenolate mofetil 
ns sg H1-AH and narrowband UV-B 
ns sg H1-AH and omalizumab 
Monotherapy 
Oxatomide 
Nifedipine 
Warfarin 
Interferon 
Plasmapheresis 
Immunoglobulins 
Autologs whole blood Injection (ASST positive only) 
High 
Very low
Low 
Low 
Very low 
Very low 
Very low 
Very low 
Very low 
Low 
Very low 
Very low 
Very low 
Very low 
Very low 
Very low
Very low 
Very low 
Very low 
Very low 
Very low 
All weak apallergy.org
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It is in the opinion of the Asian Academy of Dermatology and 
Venereology Study Group that second generation non-sedating 
antihistamines should be prescribed as first-line treatment. But 
based on extenuating circumstances where availability, costing, 
coupled with proper medical advice providing warnings about the 
adverse effects of sedation or somnolence in environments where 
the patient may be subject to harm or may be causal in harming 
others, prescription of first-generation H1-antihistamines can be 
carried out (Table 4).
Non-pharmacological and alternative approaches 
Similar with many other therapeutically challenging disorders, 
Table 3 (cont’d)
Patient population  Intervention  Strength of 
recommendation 
for use of 
intervention 
Alternative interventions (for 
patients who do not respond to 
other interventions) 
Quality of 
evidence 
Strength of 
recommend-
ation for use of 
intervention 
c. Physical urticaria Avoidance of stimuli Strong
c1. Symptomatic 
dermographism/
Urticaria factitia 
Non-sedating 
second generation 
H1-antihistamine 
Weak  Ketotifen (see also chronic urticaria) 
Narrowband UV-B therapy 
Very low 
Very low 
All weak 
c2. Delayed pressure 
urticaria 
Non-sedating 
second generation 
H1-antihistamine 
All weak  Combination therapy 
Montelukast and ns H1-AH (loratadine) 
Monotherapy 
Prednisolone 40–20 mg
Other treatment options 
Combination therapy 
Ketotifen and nimesulide 
Monotherapy 
Topical clobetasol propionate 
Sulfasalazine 
Very low 
Very low 
Very low 
Very low 
Very low 
All weak 
c3. Cold urticaria  Non-sedating 
second generation 
H1-antihistamine 
Increase dose up to 
four-fold 
Strong  Trial with penicillin i.m./p.o. 
Trial with doxycyline p.o. 
Induction of physical tolerance. 
Other treatment options 
Cyproheptadine 
Ketotifen 
Montelukast 
Very low
Very low 
Very low 
Low 
Very low 
All weak 
c4. Solar urticaria  Non-sedating H1-
antihistamine 
Weak  Induction of physical tolerance 
Other treatment options 
Plasmapheresis + PUVA 
Photopheresis 
Plasma exchange 
IVIGs 
Omalizumab 
Very low 
Very low 
Very low 
Very low 
Very low 
Very low 
All weak 
d. Cholinergic urticaria  Non-sedating H1-
antihistamine 
– Increase dosage 
if necessary 
Weak  ‘Exercise tolerance’ 
Other treatment options 
Ketotifen 
Danazol 
Omalizumab 
Very low 
Very low 
Very low 
Very low 
All weak 
ASST, autologous serum skin test; PUVA, phototherapy with ultraviolet light or photo chemotherapy. Taken from Table 3: EAACI/GA²LEN/EDF/WAO 
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chronic idiopathic urticaria has seen an abundance of fad 
therapies, including ayurvedic and homeopathic medications and 
naturopathy. Frequent tepid showers and application of soothing 
lotions can be prescribed as cooling agents when wheals erupt 
and are pruritic. These include 0.5-1% menthol or calamine in 
aqueous cream/lotion and 10% crotamiton lotion [32].
PUVA has been used for treating chronic urticaria, but the 
reported results have been inconclusive. A complementary 
psychological treatment of patients suffering from chronic idiopathic 
urticaria seems necessary, because of the high prevalence of 
psychological symptoms. Relaxation under hypnosis has produced a 
decrease in itching, but not in the number of hives [33].
Table 4. Available drug choices in Asia for treatment of chronic urticaria 
Drug name Brand or trade names in Asia Drug class
Desloratadine  Aerius Second generation non sedating H1-antihistamine (nsAH)
Ebastine  Aleva
Fexofenadine  Allegra
Loratadine  Clarityne
Mizolastine  Mizollen
Cetirizine Zyrtec Second generation mild sedating H1-antihistamine (nsAH)
Levocetirizine  Xyzal
Cyclosporine  Sandimmun Immunosuppressant 
Cimetidine  Tagamet H2-receptor antagonist antihistamines 
Dapsone Dapsone Antibacterial, Anti-inflammatory
Doxepin  Sinequan Tricyclic antidepressants 
Famotidine  Famotin H2-receptor antagonist antihistamines 
Hydroxychloroquine  Plaquenil Anti-malarial 
Indomethacin  Indocin IV vial, Non-steroidal anti-inflammatory 
Interferon  Betaferon vial, Intron-A Multidose pen, Peg-Intron 
Pre-filled Redi pen, Rebif Ready-to-use pre-filled 
syringe, Roferon-A Pre-filled syringe
Antivirals immunological chemotherapy 
Ketotifen  Zaditen Piperidine 
Methotrexate  Methotrexate Pfizer vial & Methotrexate tab Antimetabolite 
Methylprednisolone  Depo-Medrol vial, Medrol tab Corticosteroids 
Montelukast  Singulair Leukotriene receptor antagonist 
Mycophenolatemofetil  Cellcept, Myfortic Immunosuppresant 
Nifedipine Adalat Calcium channel blocker
Omalizumab  Xolair Anti-IgE antibody 
Oxatomide  Tinset tab Phenylpiperazine 
Pentoxifyllin  Trenlin SR tab, Trental 400, Anti vascular (or arterial) claudication 
Prednisolone  Deltacortril, Hostacortin H, Wysolone Corticosteroids 
Ranitidine  Zantac H2-receptor antagonist antihistamines 
Stanazolol  Winstrol Anabolic steroid 
Sulfasalazine  Salazopyrin Anti-inflammatory 
Terbutaline  Bricanyl, Dhatalin, Bricasma Antiasthmatic 
Warfarin  Coumadin Anticoagulant 
Zafirlukast  Accolate Leukotriene receptor antagonist, Antiasthmatic 
Zileuton  Zyflo Leukotriene receptor antagonist 
Due to the vast number of available drugs from each drug type across Asia, the alphabetical list provided covers proprietary, non-generic trade name drugs. apallergy.org
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Limitations 
Data regarding the racial differences of chronic urticaria in 
Asia, its epidemiology, socio-economic impact and outcomes of 
management was not covered as part of this consensus. However 
it is recognized as an important area for further investigation. 
Future editions of this consensus will endeavour to address this 
knowledge gaps where possible. 
CONCLUsION 
The quality of life with chronic urticaria is severely affected and 
management of the disease should therefore be prompt and with 
close cooperation between patient and physician. Due to the high 
variability of disease severity, an individual approach is necessary 
for each patient. As a first line, triggering factors should be avoided 
as far as possible and any associated diseases should be treated. In 
the majority of patients, symptomatic pharmacologic treatment 
is possible with new generation antihistamines, with a very low 
adverse effect profile and good patient compliance. 
In rare, non-responding patients higher dosages and alternative 
medication should be tried. Most of these, such as corticosteroids 
or cyclosporine, should be reserved for severely affected patients 
because of their unfavourable adverse effect profile. These 
treatment options exist and are discussed in detail in the text: 
second generation antihistamines (including up to four-fold 
higher; corticosteroids in severely affected patients; cyclosporine 
for patients refractory to other modalities). 
First generation sedating antihistamines should no longer 
be used as initial therapy except in those few countries where 
second generation antihistamines are not available or where 
their use outweigh their risks. Since the severity of urticaria may 
fluctuate and spontaneous remission may occur at any time, it is 
also important that the necessity for continued or alternative drug 
treatment is re-evaluated every 3-6 months. 
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